
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
GlobalData has found that the majority of disrupted clinical trials 67.3%, were due to the suspension of enrollment. The delayed initiation of planned trials follows at 18.4%, then, 14.4% of trials are currently being impacted due to slow enrollment.
For more information and findings, click






